Drug intelligence / Profile preview

NovRD

Development stage: Preclinical
Lead developer: NovMetaPharma
Modality: Small Molecules
Administration: Oral

Overview

NovRD is a first-in-class small molecule drug developed by NovMetaPharma for the treatment of chronic kidney disease (CKD). It functions by inhibiting kidney cell death and reducing inflammation in kidney tissue. The drug's mechanism of action is centered on the inhibition of Cyclophilin D (CypD), a protein that regulates the mitochondrial permeability transition pore (mPTP). By preventing the opening of the mPTP, NovRD protects mitochondrial integrity and prevents the initiation of cell death pathways, such as apoptosis and necroptosis, in renal cells, thereby slowing the progression of CKD.

Targets

PPIF (Cyclophilin D)

Beyond the preview

Go deeper on NovRD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovRD.

Explore the full profile